Identification of a protein expression signature distinguishing early from organising diffuse alveolar damage in COVID-19 patients.


Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 10 01 2023
accepted: 09 02 2023
medline: 21 7 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

Diffuse alveolar damage (DAD) is the histological expression of acute respiratory distress syndrome and characterises lung pathology due to infection with SARS-CoV-2, and other respiratory pathogens of clinical significance. DAD reflects a time-dependent immunopathological process, progressing from an early/exudative stage through to an organising/fibrotic stage, yet within an individual these different stages of DAD may coexist. Understanding the progression of DAD is central to the development of new therapeutics to limit progressive lung damage. Here, we applied highly multiplexed spatial protein profiling to autopsy lung tissues derived from 27 patients who died from COVID-19 and identified a protein signature (ARG1, CD127, GZMB, IDO1, Ki67, phospho-PRAS40 (T246) and VISTA) that distinguishes early DAD from late DAD with good predictive accuracy. These proteins warrant further investigation as potential regulators of DAD progression.

Identifiants

pubmed: 36894313
pii: jcp-2023-208771
doi: 10.1136/jcp-2023-208771
pmc: PMC10423525
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

561-565

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Histopathology. 2021 Mar;78(4):542-555
pubmed: 32926596
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
J Pathol. 2022 Mar;256(3):256-261
pubmed: 34859884
Virchows Arch. 2004 Oct;445(4):375-81
pubmed: 15480769
Respir Res. 2022 Sep 12;23(1):242
pubmed: 36096801
J Pathol. 2021 Jan;253(1):31-40
pubmed: 32930394
Bioinformatics. 2005 Oct 15;21(20):3940-1
pubmed: 16096348
Nat Commun. 2020 Oct 8;11(1):5086
pubmed: 33033248
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
Mod Pathol. 2021 Aug;34(8):1444-1455
pubmed: 33883694
Lancet Respir Med. 2022 Jan;10(1):95-106
pubmed: 34871544
J Exp Med. 2022 Feb 7;219(2):
pubmed: 35015026
Front Immunol. 2021 Feb 11;11:595950
pubmed: 33643285
Front Immunol. 2021 Jul 14;12:695972
pubmed: 34341659
Nature. 2021 May;593(7860):564-569
pubmed: 33780969
Tohoku J Exp Med. 2014;234(1):67-75
pubmed: 25186104

Auteurs

Helen Ashwin (H)

York Biomedical Research Institute, Hull York Medical School, University of York, York, UK.

Luke Milross (L)

Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.

Julie Wilson (J)

Department of Mathematics, University of York, York, UK.

Joaquim Majo (J)

Department of Cellular Pathology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.

Jimmy Tsz Hang Lee (JT)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.

Grant Calder (G)

Biosciences Technology Facility, University of York, York, UK.

Bethany Hunter (B)

Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.

Sally James (S)

Biosciences Technology Facility, University of York, York, UK.

Dimitris Lagos (D)

York Biomedical Research Institute, Hull York Medical School, University of York, York, UK.

Nathalie Signoret (N)

York Biomedical Research Institute, Hull York Medical School, University of York, York, UK.

Andrew Filby (A)

Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Omer Ali Bayraktar (OA)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.

Andrew J Fisher (AJ)

Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK paul.kaye@york.ac.uk a.j.fisher@newcastle.ac.uk.
Institute of Transplantation, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.

Paul M Kaye (PM)

York Biomedical Research Institute, Hull York Medical School, University of York, York, UK paul.kaye@york.ac.uk a.j.fisher@newcastle.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH